Rockwell Medical prelim Q4 revenue rises

Rockwell Medical

20/01/2026 11:08

Overview

Healthcare company's preliminary Q4 revenue rises, cash flow positive for second time in 2025

Company expects Q4 gross margin to rise to 22%, up from 14% in Q3

Outlook

Company focuses on revenue growth, profitability, and portfolio diversification for 2026

Result Drivers

REVENUE INCREASE - Rockwell Medical reported a considerable increase in preliminary Q4 revenue, exceeding analyst expectations

GROSS MARGIN IMPROVEMENT - preliminary Q4 gross margin rose to 22%, up from 14% in Q3, due to improved operational efficiencies and reduced expenses

CASH FLOW POSITIVE - Company achieved positive cash flow from operations in Q4, marking the second positive quarter in 2025

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Sales
Beat
$18.60 mln
$16.55 mln (2 Analysts)

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the pharmaceuticals peer group is "buy"

Wall Street's median 12-month price target for Rockwell Medical Inc is $3.75, about 291.7% above its January 16 closing price of $0.96

Press Release: ID:nBw205KS8a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)